The EPS projection of Abbott Laboratories (NYSE:ABT) for quarter ended 2016-09-30 is $0.59. Last week, the EPS forecast was $0.59 against target of $0.59, a month earlier. Two months ago, this estimate was $0.59 versus forecast of $0.59 three months earlier, implying a deviation of 0%.
Abbott Laboratories (NYSE:ABT) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 3.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 7, 2, and 7, correspondingly.
EPS estimate downgrade for Abbott Laboratories (NYSE:ABT) in the preceding 30, 120, 60 and 90 days were 0, 1, 0, and 1, correspondingly.
Abbott Laboratories (NYSE:ABT) EPS target for the quarter closed 1 was $0.59, based on 12 recommendations. As reported on 2016-04-20 the EPS was $0.41. The change was $0.02, implying a percentage deviation of 5.13%. The projections showed a standard deviation of 0.01.
Quarterly Sales Estimates
Abbott Laboratories (NYSE:ABT) yearly sales prediction for the fiscal 2018 stands at $6112.1 and the median estimate is at $6112.1. Almost 2 analysts issued sales target.
Highest sales target is $6142 while the lowest target is $6082.2 showing standard deviation of 42.284%.
As many as 2 analysts have sales targets revised upside while 2 reduced sales estimates, implying a deviation of 0%.
Last month, 2 revised sales number projection on upside while 2 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast. Abbott Laboratories (NYSE:ABT) announced that the deviation in forecast was 1.02%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...